Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1, targeting the key und
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.